Fig. 2: Performance evaluation of MAARS and the current clinical SCDA risk assessment tools.
From: Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy
a, Receiver operating characteristic curves and AUROC values (data presented as mean values with 95% CIs) from the internal fivefold cross-validation on the JHH-HCM cohort (n = 553). b, Receiver operating characteristic curves and AUROC values (data presented as mean values with 95% CIs) from the external validation on the SHVI-HCM cohort (n = 286). c, Distributions of predicted SCDA risk scores, with blue bars and curves for patients not experiencing SCDA and red bars and curves for patients experiencing SCDA. Two-sample Kolmogorov–Smirnov tests were conducted to quantify the distance of the distributions for SCDA and no SCDA and to obtain the P values. The dashed vertical line indicates the optimal decision threshold for each predictor, and the shaded gray area on the right of the thresholds indicates patients predicted to have a high risk for SCDA. K–S, Kolmogorov–Smirnov statistic.
